for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hualan Biological Engineering Inc

002007.SZ

Latest Trade

28.32CNY

Change

0.15(+0.53%)

Volume

17,185,422

Today's Range

28.01

 - 

28.74

52 Week Range

26.90

 - 

65.00

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
28.17
Open
28.21
Volume
17,185,422
3M AVG Volume
427.18
Today's High
28.74
Today's Low
28.01
52 Week High
65.00
52 Week Low
26.90
Shares Out (MIL)
1,823.47
Market Cap (MIL)
51,392.41
Forward P/E
27.25
Dividend (Yield %)
1.06

Next Event

Q3 2021 Hualan Biological Engineering Inc Earnings Release

Latest Developments

More

Hualan Biological Engineering's Vaccine Unit Gets Exchange's Nod For IPO

Hualan Biological Engineering's Operation Hindered by Torrential Rain

Hualan Biological Engineering's 2020 Net Profit Up 25.7% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hualan Biological Engineering Inc

HUALAN BIOLOGICAL ENGINEERING, INC. is a China-based company principally engaged in the research, development, production and sales of blood products. It also produces vaccine products and biological engineering products. The Company's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The Company mainly operates its businesses in domestic markets.

Industry

Biotechnology & Drugs

Contact Info

No.A1, Hualan Avenue

XINXIANG, HEN

453003

China

+86.373.3559989

http://english.hualanbio.com

Executive Leadership

Kang An

Chairman of the Board, General Manager

Junmin Xie

Chief Financial Officer, Secretary of the Board

Bei Fan

Executive Deputy General Manager, Director

Qiping Wang

Deputy General Manager, Director

Wenqi An

Deputy General Manager

Key Stats

1.95 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

3.2K

2019

3.7K

2020

5.0K

2021(E)

5.8K
EPS (CNY)

2018

0.628

2019

0.706

2020

0.886

2021(E)

1.034
Price To Earnings (TTM)
32.78
Price To Sales (TTM)
10.43
Price To Book (MRQ)
6.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.78
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
25.42
Return on Equity (TTM)
20.63

Latest News

Latest News

BRIEF-Shenzhen Exchange Filing Shows Block Trade Of Hualan Biological Engineering's Shares Involving 458.3 Mln Yuan

* BLOCK TRADE OF HUALAN BIOLOGICAL ENGINEERING INC'S 12.1 MILLION SHARES INVOLVING 458.3 MILLION YUAN ($64.20 million) ON MAY 29 Source text in Chinese: https://bit.ly/2TQtmDH Further company coverage: ($1 = 7.1390 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shenzhen Exchange Filing Shows Block Trade Of Hualan Biological's Shares Involving 190 Mln Yuan

* FILING SHOWS BLOCK TRADE OF HUALAN BIOLOGICAL ENGINEERING INC'S 5 MILLION SHARES INVOLVING 190 MILLION YUAN ($26.55 million) ON MAY 28 Source text in Chinese: https://bit.ly/2Aj3EkA Further company coverage: ($1 = 7.1570 Chinese yuan renminbi) (Reporting by Hong Kong newsroom...

BRIEF-Shenzhen Stock Exchange Filing Shows Block Trade Of Hualan Biological Engineering's Shares Involving 170.2 Mln Yuan

* BLOCK TRADE OF HUALAN BIOLOGICAL ENGINEERING INC'S 4.5 MILLION SHARES INVOLVING 170.2 MILLION YUAN ($23.97 million) ON MAY 21 Source text in Chinese: https://bit.ly/2A1megD Further company coverage: ($1 = 7.1001 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shenzhen Stock Exchange Filing Shows Block Trade Of Hualan Biological Engineering's Shares Involving 252.9 Mln Yuan

* BLOCK TRADE OF HUALAN BIOLOGICAL ENGINEERING INC'S 7.0 MILLION SHARES INVOLVING 252.9 MILLION YUAN ($35.73 million) ON MAY 8 Source text in Chinese: https://bit.ly/2LerXly Further company coverage: ($1 = 7.0787 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Hualan Biological Engineering Plans To List Vaccine Unit On Shenzhen Chinext Board

* SAYS IT PLANS TO SPIN-OFF ITS VACCINE UNIT AND TO LIST IN SHENZHEN CHINEXT BOARD Source text in Chinese: https://reurl.cc/nzDmAl Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Hualan Biological Engineering's Q1 Net Profit Down 4.7% Y/Y

* SAYS Q1 NET PROFIT DOWN 4.7% Y/Y AT 247.3 MILLION YUAN ($35.04 million) Source text in Chinese: https://bit.ly/2yxKeav Further company coverage: ($1 = 7.0568 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Hualan Biological Engineering's 2019 Net Profit Up 12.6% Y/Y

* SAYS 2019 NET PROFIT UP 12.6% Y/Y AT 1.3 BILLION YUAN ($183.53 million) Source text in Chinese: https://bit.ly/2UyGE7D Further company coverage: ($1 = 7.0832 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Hualan Biological Engineering's Prelim 2019 Net Profit Up 12.6% Y/Y

* SAYS PRELIM 2019 NET PROFIT UP 12.6% Y/Y AT 1.3 BILLION YUAN Source text in Chinese: https://reurl.cc/6gpOd5 Further company coverage: (Reporting by Hong Kong newsroom)

REFILE-BRIEF-Hualan Biological Engineering Says Q3 Net Profit Up 63.15 Percent Y/Y

* SAYS Q3 NET PROFIT UP 63.15 PERCENT Y/Y Source text in Chinese: https://bit.ly/2CNvGUn Further company coverage: (Reporting by Hong Kong newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up